Ashwagandha for Cognitive Function

Ashwagandha is one of a small number of botanicals with documented cognitive benefit in randomized controlled trials — not just in healthy young adults seeking mental performance enhancement, but in older adults with mild cognitive impairment (MCI), a population where most interventions fail. The pivotal trial — Choudhary, Bhattacharyya, and Bose 2017, published in the Journal of Dietary Supplements — randomized 50 adults with MCI to 300 mg of KSM-66 root extract twice daily or placebo for 8 weeks. The active treatment group showed statistically significant improvements in immediate and general memory (Wechsler Memory Scale), executive function (Trail Making Test), sustained attention (Eriksen Flanker), and information-processing speed (Mackworth Clock Test). The mechanism has been mapped at the cellular level by Sehgal, Bhatnagar, and Wadhwa in their 2012 PNAS paper showing that withanolide A and withanoside IV reverse beta-amyloid-induced synaptic loss and stimulate neurite outgrowth in cell culture, with downstream implications for Alzheimer's and Parkinson's research. This page covers the cognitive trial evidence, the cellular mechanisms (cholinergic activity, BDNF, neurite outgrowth, beta-amyloid reversal), the comparison with bacopa, lion's mane, and other nootropic botanicals, and the practical application to mild cognitive impairment, normal age-related cognitive decline, and exam-period mental performance in younger adults.

The Choudhary 2017 MCI Trial
The Sehgal 2012 Beta-Amyloid Reversal Mechanism
Cholinergic Activity and Acetylcholine Signaling
Neurite Outgrowth and Synaptic Reconstruction
BDNF and Adult Neuroplasticity
Nrf2 Activation and Neuroprotection from Oxidative Stress
Alzheimer's Disease Research and Translation Status
Parkinson's Disease and Neurodegenerative Models
Application in Young Adults and Exam-Period Performance
Comparison with Bacopa, Lion's Mane, and Other Nootropics
Dosing for Cognitive Indications
Cautions
Key Research Papers
Connections

The Choudhary 2017 MCI Trial

Choudhary, Bhattacharyya, and Bose published the most cited cognitive trial of Ashwagandha in the Journal of Dietary Supplements in 2017. The design was a prospective, randomized, double-blind, placebo-controlled study in 50 adults aged 35-75 with mild cognitive impairment (MCI) — defined as subjective cognitive complaint with objective evidence of impairment on neuropsychological testing, but without dementia.

Subjects were randomized 1:1 to receive either 300 mg of KSM-66 root extract twice daily, or matched placebo, for 8 weeks. The neuropsychological battery included the Wechsler Memory Scale-III (logical memory, faces, family pictures, verbal paired associates), the Trail Making Test (executive function, working memory, set-shifting), the Eriksen Flanker Test (selective attention, response inhibition), and the Mackworth Clock Test (sustained attention and vigilance).

Results at 8 weeks (Ashwagandha vs placebo):

Logical memory (immediate) — 13.8% improvement vs 4.5%
Logical memory (delayed recall) — 22.0% improvement vs 9.5%
Verbal paired associates (immediate) — significant improvement in active group only
Faces (immediate and delayed) — significant improvement in active group only
Trail Making Test A (visual scanning, motor speed) — faster completion times
Trail Making Test B (executive function, working memory) — significant improvement
Eriksen Flanker reaction time — faster and more accurate
Mackworth Clock Test (sustained attention) — significant improvement
Adverse events — mild and indistinguishable from placebo

The pattern of improvement is notable for being broad — multiple cognitive domains improved, not just one. This is consistent with a mechanism that affects general neural function (cholinergic transmission, BDNF, oxidative stress) rather than one that targets a specific cognitive faculty (a pure mnemonic, for example).

A 2014 Pingali trial in 20 healthy male subjects (no cognitive impairment) using KSM-66 at 500 mg/day for 14 days also documented improvement in reaction time on the Discrimination Reaction Time test, sustained attention on the Mackworth, and executive function on the Trail Making Test. The effect in healthy subjects is smaller in absolute magnitude than in the MCI population but still measurable.

Back to Table of Contents

The Sehgal 2012 Beta-Amyloid Reversal Mechanism

The most striking mechanistic finding in Ashwagandha cognitive pharmacology came from Sehgal, Bhatnagar, and Wadhwa, working at the Council of Scientific and Industrial Research in India and the National Institute of Advanced Industrial Science and Technology in Japan. Their 2012 paper in Proceedings of the National Academy of Sciences demonstrated that Withania somnifera root extract can reverse cognitive deficits and beta-amyloid pathology in a mouse model of Alzheimer's disease.

The experimental design used APP/PS1 transgenic mice that overexpress mutant human amyloid precursor protein and presenilin-1 — producing the cardinal pathology of Alzheimer's disease (extracellular amyloid plaque deposition in cortex and hippocampus, synaptic loss, cognitive deficits in spatial learning and memory). Mice were treated with oral Ashwagandha extract at a dose equivalent to human therapeutic dosing, for 30 days.

Findings:

Plaque load reduction — amyloid plaques in cortex and hippocampus were significantly reduced in treated mice
Soluble beta-amyloid reduction — both Abeta-40 and Abeta-42 species were reduced in brain tissue
Cognitive reversal — performance on the Morris Water Maze (spatial learning and memory) returned to wild-type baseline in treated transgenic mice
Mechanism is peripheral, not central — the surprising finding. Ashwagandha's effect on brain amyloid was mediated by upregulation of liver LRP (low-density lipoprotein receptor-related protein), which acts as a peripheral sink to clear soluble beta-amyloid from plasma. The brain-to-blood concentration gradient then drove amyloid efflux out of the central nervous system.

This peripheral-sink mechanism was a major conceptual contribution — it provided a rationale for how a botanical might affect brain pathology without itself crossing the blood-brain barrier in pharmacologically meaningful concentrations. The withanolide compounds enter the liver, upregulate hepatic LRP, and the peripheral clearance of amyloid pulls brain amyloid down through equilibrium.

Earlier in 2012, the same group (Kuboyama et al., extending Sehgal's 2002 work on withanoside IV) had also demonstrated that withanolide A and withanoside IV directly stimulate neurite outgrowth, dendritic branching, and synaptic reconstruction in neuronal cell cultures damaged by beta-amyloid. The combined picture is one of both clearance (peripheral sink) and rebuilding (synaptic regeneration) — the two arms of any plausible disease-modifying therapy for Alzheimer's disease.

The translation to human clinical Alzheimer's disease has not yet been established with adequate trials. The Choudhary 2017 MCI trial is the closest evidence and is encouraging, but a Phase 3 trial in mild-to-moderate Alzheimer's disease has not been completed. Ashwagandha remains experimental and adjunctive in the AD context, not a substitute for FDA-approved disease-modifying therapies.

Back to Table of Contents

Cholinergic Activity and Acetylcholine Signaling

Acetylcholine is the principal neurotransmitter of the basal forebrain cholinergic system, which projects to the cortex and hippocampus and is essential for attention, learning, and memory consolidation. The progressive loss of basal forebrain cholinergic neurons is one of the cardinal pathologies of Alzheimer's disease, and the FDA-approved AD drugs (donepezil, rivastigmine, galantamine) all work by inhibiting acetylcholinesterase to prolong synaptic acetylcholine action.

Schliebs and colleagues at the Paul Flechsig Institute in Leipzig published in Neurochemistry International in 1997 the first demonstration that Withania somnifera extract increases cortical muscarinic acetylcholine receptor binding in rats. The mechanism is upregulation of the receptor protein itself, not acetylcholinesterase inhibition. The functional consequence is enhanced cholinergic transmission with the same amount of released acetylcholine — the post-synaptic side of the synapse becomes more responsive.

Subsequent work has shown that withanolides also support choline acetyltransferase activity (the enzyme that synthesizes acetylcholine from choline and acetyl-CoA), modestly increase basal forebrain cholinergic neuron survival in toxin-lesion models, and may have weak direct AChE-inhibitory activity at high concentrations.

The cholinergic mechanism is the most likely explanation for the cognitive performance improvements in the Choudhary and Pingali trials — attention, working memory, and reaction time are all cholinergic-sensitive cognitive domains.

Back to Table of Contents

Neurite Outgrowth and Synaptic Reconstruction

Beyond neurotransmitter signaling, Ashwagandha withanolides act as direct trophic factors for neurons. The Kuboyama, Tohda, and Komatsu series of papers (in British Journal of Pharmacology 2005, European Journal of Neuroscience 2002, and subsequent extensions) demonstrated that withanolide A and withanoside IV — or their in-vivo active metabolite sominone — stimulate neurite outgrowth in cultured neurons.

The relevant findings:

In SH-SY5Y human neuroblastoma cells and rat cortical neurons, withanolide A increased axon length, dendritic branching, and the number of post-synaptic specializations
In neurons damaged by beta-amyloid 25-35 fragment exposure, withanoside IV reversed both axonal and dendritic atrophy and restored synaptic protein expression (synaptophysin, PSD-95)
In whole mouse brain after intracerebroventricular Abeta injection, oral withanoside IV reversed memory deficits on the Morris Water Maze and restored synaptic density in cortex and hippocampus
The active metabolite responsible for in-vivo activity was identified as sominone, an aglycone produced when intestinal bacteria deglycosylate withanoside IV

The implication is dramatic: Ashwagandha withanolides do not merely slow neurodegeneration; in cell-culture and rodent models, they actively rebuild synaptic networks that have been damaged. Whether this translates to clinical neurodegenerative disease in humans is the open Phase 3 question. The existing MCI trial evidence is consistent with a regenerative effect but not definitive.

Back to Table of Contents

BDNF and Adult Neuroplasticity

Brain-derived neurotrophic factor (BDNF) is the master regulator of adult neuroplasticity — the protein that supports neuron survival, the growth of new dendritic spines and synapses, and the expression of long-term potentiation that underlies learning. Chronic stress, depression, and aging all reduce BDNF expression in the hippocampus and prefrontal cortex. Exercise, learning, and most effective antidepressants increase BDNF.

Ashwagandha increases BDNF expression in both rodent models and limited human studies. The mechanism appears to involve direct withanolide-mediated upregulation of BDNF gene transcription, combined with reduced cortisol (which itself suppresses BDNF), combined with Nrf2-mediated reduction in oxidative stress (which damages BDNF signaling).

The BDNF mechanism is particularly relevant for the antidepressant signal seen in some Ashwagandha trials, and for the cognitive-protective effect under chronic stress conditions. It also links Ashwagandha to other interventions that increase BDNF — aerobic exercise, intermittent fasting, ketogenic diet, lion's mane mushroom, and saffron extract — that may be additively beneficial when combined.

Back to Table of Contents

Nrf2 Activation and Neuroprotection from Oxidative Stress

Withaferin A — the most pharmacologically active withanolide, present at high concentration in the leaves and at modest concentration in the roots — is a potent activator of the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor. Nrf2 normally exists in the cytoplasm bound to its inhibitor Keap1, but cellular oxidative stress modifies Keap1 cysteine residues and releases Nrf2 to translocate to the nucleus, where it binds antioxidant response elements (AREs) in the promoters of more than 200 cytoprotective genes.

The Nrf2-induced gene set includes:

Glutathione synthesis enzymes (GCLC, GCLM) that produce the cell's primary intracellular antioxidant
NAD(P)H quinone dehydrogenase 1 (NQO1) for detoxification of quinone metabolites
Heme oxygenase 1 (HO-1) for heme catabolism and anti-inflammatory bilirubin production
Superoxide dismutase 1 (SOD1) and catalase
Phase 2 detoxification enzymes (glutathione S-transferases, UDP-glucuronyltransferases)

Withaferin A is one of the most potent natural Nrf2 activators known. In neurons, this translates to substantial protection against oxidative stress-induced damage from rotenone (Parkinson's model toxin), 6-OHDA (another PD model), MPTP, and beta-amyloid. The neuroprotective effect is mechanistically separate from the cholinergic and neurite-outgrowth effects and may be additively beneficial in any neurodegenerative process where oxidative damage is a driving factor.

The Nrf2 mechanism is also the basis for the anti-inflammatory and anti-cancer signal in withaferin A — the same Nrf2 program reduces NF-kappa-B-driven inflammation and induces apoptosis in transformed cells. Pharmaceutical chemistry programs have been pursuing withaferin A derivatives as anti-cancer leads.

Back to Table of Contents

Alzheimer's Disease Research and Translation Status

The translation of Ashwagandha's preclinical AD activity to human clinical trials has been slow. The most directly relevant clinical data is the Choudhary 2017 MCI trial discussed above. There is no completed Phase 3 trial of Ashwagandha in diagnosed Alzheimer's disease.

The barriers are familiar:

Funding for botanical medicine trials in AD is limited (pharmaceutical sponsors prefer patentable single molecules)
Standardization concerns — even within KSM-66 and Sensoril, batch-to-batch variation in withanolide content is real
Trial design challenges — AD progression is slow, requiring 18-36 month trials with hundreds to thousands of subjects to detect modest disease-modifying effects
The FDA pathway for botanical drugs is narrow (only one botanical — Veregen sinecatechins for genital warts — has been approved through the formal botanical drug pathway in the past 20 years)

Current best practice in integrative medicine: Ashwagandha is a reasonable adjunctive supplement for patients with MCI or early AD, in combination with the standard cardiovascular risk-factor management, exercise, sleep, social engagement, and (when indicated) cholinesterase inhibitors and the amyloid-targeting monoclonal antibodies (donanemab, lecanemab). It should not be presented as a substitute for or alternative to evidence-based AD care.

See our Alzheimer's Disease page for the broader clinical context.

Back to Table of Contents

Parkinson's Disease and Neurodegenerative Models

The Parkinson's disease preclinical literature is smaller but encouraging. Ashwagandha root extract has been shown to protect dopaminergic neurons in the substantia nigra against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), rotenone, and 6-OHDA toxin lesions in rodent models. The mechanism involves both Nrf2-mediated antioxidant induction and modulation of dopamine receptor expression.

RajaSankar and colleagues published in Journal of Ethnopharmacology in 2009 the first demonstration that Withania somnifera root extract reverses behavioral, biochemical, and histological correlates of MPTP-induced Parkinson's disease in mice. Subsequent work has confirmed the protective effect with extracts standardized to varying withanolide content.

Clinical translation in Parkinson's disease has been even more limited than in AD. There is no Phase 3 RCT. The mechanistic plausibility is strong, but the human evidence is essentially absent. Patients with PD considering Ashwagandha should view it as adjunctive and unproven for that indication specifically, while it remains well-supported for the stress, sleep, and cognitive support that PD patients often need alongside their dopaminergic therapy.

Back to Table of Contents

Application in Young Adults and Exam-Period Performance

The Pingali 2014 trial in 20 healthy male subjects established that even in cognitively normal young adults, KSM-66 at 500 mg/day for 14 days produces measurable improvement on reaction time, attention, and executive function tests. This is the basis for the popular use of Ashwagandha as a "natural nootropic" by students, professionals in cognitively demanding fields, and athletes.

The honest assessment is that the magnitude of cognitive benefit in healthy young adults is modest — perhaps a 5-10% improvement in reaction time and sustained attention — and the effect is most pronounced under conditions of stress, fatigue, or sleep restriction (which Ashwagandha's cortisol-lowering and sleep-supporting mechanisms naturally address). In a well-rested, well-fed, low-stress young adult performing optimally already, Ashwagandha's pure cognitive enhancement effect is small.

The most appropriate use case in young adults is therefore as a stress-resilience aid during high-demand periods (exam weeks, project deadlines, competitive athletic seasons) where the secondary cognitive benefit emerges from prevented cognitive decline rather than from baseline enhancement. For pure mental performance enhancement in healthy adults, modafinil or caffeine produce larger and faster effects with their own respective trade-offs.

Back to Table of Contents

Comparison with Bacopa, Lion's Mane, and Other Nootropics

Among botanical cognitive supports with reasonable evidence:

Bacopa monnieri — the most established botanical nootropic in the literature, with multiple RCTs demonstrating improvement in memory and learning in both older adults and healthy young adults. Bacosides A and B are the active compounds. Effect emerges over 8-12 weeks of consistent use. Mechanism includes cholinergic facilitation and antioxidant activity. Often paired with Ashwagandha in Ayurvedic medhya rasayana (mind-rejuvenating) formulas. See our Bacopa page.
Lion's mane (Hericium erinaceus) — the most promising mushroom nootropic. Hericenones and erinacines stimulate nerve growth factor (NGF) production, supporting peripheral and central nervous system repair. One Japanese RCT in 30 adults with MCI showed cognitive improvement that disappeared on discontinuation. Mechanistically complementary to Ashwagandha (NGF vs BDNF).
Ginkgo biloba — the most widely sold cognitive supplement globally. Multiple RCTs in older adults; meta-analyses are mixed with publication-bias concerns. Vasodilation and antioxidant mechanisms. Less impressive evidence base than its market share would suggest.
Ginseng (Panax ginseng and Panax quinquefolius) — modest cognitive effects in some trials, particularly for sustained attention and reaction time. American ginseng (Panax quinquefolius) has a particularly good RCT in working memory.
Phosphatidylserine — not a botanical but worth mentioning. A membrane phospholipid that supports memory in older adults with cognitive complaints. Most data with bovine-derived phosphatidylserine; modern products use soy-derived.

For someone designing a cognitive support stack from the botanical evidence base, a reasonable starting protocol is Ashwagandha (300 mg twice daily) plus Bacopa (300 mg standardized to 50% bacosides daily) plus Lion's Mane (500-1000 mg twice daily). All three are slow-acting (6-12 weeks for full effect), all are well-tolerated, and the mechanisms are complementary.

Back to Table of Contents

Dosing for Cognitive Indications

Mild cognitive impairment / older adults with cognitive complaints — 300 mg KSM-66 twice daily (the Choudhary protocol), or 500 mg KSM-66 daily, taken with meals. Allow 8-12 weeks for full effect. Re-assess with a cognitive battery (Montreal Cognitive Assessment, Mini-Mental State) at baseline and at 12 weeks.
Healthy young adult cognitive support — 300-500 mg KSM-66 daily, taken with breakfast. Effect is modest; expect small gains under stress rather than large gains at baseline.
Stacked nootropic protocol — Ashwagandha 300 mg twice daily + Bacopa 300 mg daily + Lion's Mane 1000 mg daily, taken with meals. The three botanicals are complementary; full effect at 8-12 weeks.
Adjunctive in Alzheimer's or Parkinson's disease — 300 mg KSM-66 twice daily as adjunct to standard medical therapy. Coordinate with treating neurologist. Not a substitute for cholinesterase inhibitors, NMDA antagonists, amyloid-targeting antibodies, or dopaminergic therapy as appropriate.

Back to Table of Contents

Cautions

Not a substitute for evidence-based dementia care — patients and families considering Ashwagandha for AD or vascular dementia should also have access to neurologist evaluation, cholinesterase inhibitors if indicated, blood pressure and lipid optimization, exercise prescription, and the structured social and cognitive engagement that have the strongest evidence base.
Pregnancy — absolute contraindication.
Hyperthyroidism — relative contraindication. Cognitive complaints in hyperthyroid patients should be addressed by thyroid management first.
Sedative interaction — additive with benzodiazepines, opioids, alcohol; relevant for older adults at risk of falls or cognitive impairment from polypharmacy.
Thyroid medication interaction — recheck TSH 6-8 weeks after starting Ashwagandha in patients on levothyroxine.
Hepatotoxicity case reports — rare. Check liver function tests at baseline and periodically in long-term use.
Driving and cognitive testing — in the first 1-2 weeks some patients experience mild grogginess. Avoid initiating Ashwagandha on the day of a cognitive evaluation that will inform clinical decision-making.

Back to Table of Contents

Key Research Papers

Choudhary D, Bhattacharyya S, Bose S (2017). Efficacy and safety of ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions. Journal of Dietary Supplements. — PubMed
Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012). Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. PNAS. — PubMed
Kuboyama T, Tohda C, Komatsu K (2005). Neuritic regeneration and synaptic reconstruction induced by withanolide A. British Journal of Pharmacology. — PubMed
Tohda C, Kuboyama T, Komatsu K (2000). Dendrite extension by methanol extract of ashwagandha (roots of Withania somnifera) in SK-N-SH cells. NeuroReport. — PubMed
Pingali U, Pilli R, Fatima N (2014). Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Research. — PubMed
Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V (1997). Systemic administration of defined extracts from Withania somnifera and shilajit differentially affect cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochemistry International. — PubMed
RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S (2009). Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. Journal of Ethnopharmacology. — PubMed
Manchanda S, Mishra R, Singh R, Kaur T, Kaur G (2017). Aqueous leaf extract of Withania somnifera as a potential neuroprotective agent in sleep-deprived rats. Molecular Neurobiology. — PubMed
Choudhary D, Bhattacharyya S, Joshi K (2017). Body weight management in adults under chronic stress through treatment with ashwagandha root extract: a double-blind, randomized, placebo-controlled trial. Journal of Evidence-Based Complementary and Alternative Medicine. — PubMed
Singh N, Bhalla M, de Jager P, Gilca M (2011). An overview on ashwagandha: a rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines. — PubMed
Mishra LC, Singh BB, Dagenais S (2000). Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Alternative Medicine Review. — PubMed
Kuboyama T, Tohda C, Komatsu K (2014). Effects of ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. Biological and Pharmaceutical Bulletin. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents